Movement Alert｜CARsgen Therapeutics Intraday Decline 7.49%, Profit-Taking After Historic Solid Tumor CAR-T Approval

Market Focus06-23

On June 23, CARsgen Therapeutics (02171.HK) fell 7.49% in regular trading to HKD 15.51/share, with turnover of HKD 172 million.

On the news front, the company announced on June 22 that China's NMPA approved its self-developed Claudin18.2 autologous humanized CAR-T product Satri-Cel (舒瑞基奥仑赛注射液, brand name: Kailimei) for new drug marketing, marking the world's first CAR-T cell therapy approved for solid tumor treatment. The product is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma patients who have failed at least two prior systemic therapies. The company's chairman stated this achievement represents a breakthrough from zero to one in translating original lab innovations into clinical applications after nearly a decade of research.

Despite the landmark regulatory milestone, the stock experienced notable selling pressure, suggesting the approval had been widely anticipated and largely priced in ahead of the official announcement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164809697?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 10:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164809697","market":"us","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics Intraday Decline 7.49%, Profit-Taking After Historic Solid Tumor CAR-T Approval","media":"Market Focus","content":"<p><p>On June 23, CARsgen Therapeutics (02171.HK) fell 7.49% in regular trading to HKD 15.51/share, with turnover of HKD 172 million.</p><p>On the news front, the company announced on June 22 that China's NMPA approved its self-developed Claudin18.2 autologous humanized CAR-T product Satri-Cel (舒瑞基奥仑赛注射液, brand name: Kailimei) for new drug marketing, marking the world's first CAR-T cell therapy approved for solid tumor treatment. The product is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma patients who have failed at least two prior systemic therapies. The company's chairman stated this achievement represents a breakthrough from zero to one in translating original lab innovations into clinical applications after nearly a decade of research.</p><p>Despite the landmark regulatory milestone, the stock experienced notable selling pressure, suggesting the approval had been widely anticipated and largely priced in ahead of the official announcement.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics Intraday Decline 7.49%, Profit-Taking After Historic Solid Tumor CAR-T Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics Intraday Decline 7.49%, Profit-Taking After Historic Solid Tumor CAR-T Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 10:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, CARsgen Therapeutics (02171.HK) fell 7.49% in regular trading to HKD 15.51/share, with turnover of HKD 172 million.</p><p>On the news front, the company announced on June 22 that China's NMPA approved its self-developed Claudin18.2 autologous humanized CAR-T product Satri-Cel (舒瑞基奥仑赛注射液, brand name: Kailimei) for new drug marketing, marking the world's first CAR-T cell therapy approved for solid tumor treatment. The product is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma patients who have failed at least two prior systemic therapies. The company's chairman stated this achievement represents a breakthrough from zero to one in translating original lab innovations into clinical applications after nearly a decade of research.</p><p>Despite the landmark regulatory milestone, the stock experienced notable selling pressure, suggesting the approval had been widely anticipated and largely priced in ahead of the official announcement.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1164809697","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164809697","pubTimestamp":1782182026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, CARsgen Therapeutics (02171.HK) fell 7.49% in regular trading to HKD 15.51/share, with turnover of HKD 172 million.On the news front, the company announced on June 22 that China's NMPA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"动静快讯|科济生物盘中跌7.49%实体瘤CAR-T历史性获批后获利了结","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On June 23, CARsgen Therapeutics (02171.HK) fell 7.49% in regular trading to HKD 15.51/share, with turnover of HKD 172 million.On the news front, the company announced on June 22 that China's NMPA approved its self-developed Claudin18.2 autologous humanized CAR-T product Satri-Cel (舒瑞基奥仑赛注射液, brand name: Kailimei) for new drug marketing, marking the world's first CAR-T cell therapy approved for solid tumor treatment. The product is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma patients who have failed at least two prior systemic therapies. The company's chairman stated this achievement represents a breakthrough from zero to one in translating original lab innovations into clinical applications after nearly a decade of research.Despite the landmark regulatory milestone, the stock experienced notable selling pressure, suggesting the approval had been widely anticipated and largely priced in ahead of the official announcement.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164809697","isCrawlerRequest":true}